Alnylam Pharmaceuticals, Inc. (BVMF:A1LN34)

Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions BRL. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 10, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	316,918	187,715	116,555	154,568	113,005	78,417
Market Cap Growth	50.67%	61.05%	-24.59%	36.78%	44.11%	51.93%
Enterprise Value	317,175	187,381	117,806	156,293	110,728	76,021
Last Close Price	120.96	72.73	44.65	63.00	47.03	31.95
PS Ratio	18.52	13.50	13.14	28.18	24.02	30.64
PB Ratio	254.24	452.40	-108.87	-184.79	34.48	14.86
P/TBV Ratio	254.24	452.40	-	-	34.48	14.86
P/FCF Ratio	268.63	-	572.67	-	-	-
P/OCF Ratio	223.67	-	230.62	-	-	-
EV/Sales Ratio	18.70	13.48	13.28	28.50	23.54	29.70
EV/FCF Ratio	268.85	-	578.81	-	-	-
Debt / Equity Ratio	11.86	40.89	-12.16	-16.51	3.72	1.57
Debt / FCF Ratio	12.53	-	63.96	-	-	-
Asset Turnover	0.71	0.56	0.50	0.29	0.24	0.17
Inventory Turnover	6.83	3.86	2.85	1.57	1.74	1.19
Quick Ratio	2.37	2.61	2.86	3.17	3.79	4.23
Current Ratio	2.54	2.78	3.08	3.51	4.04	4.47
Return on Equity (ROE)	32.73%	-	-	-526.14%	-106.31%	-69.92%
Return on Assets (ROA)	3.65%	-2.74%	-4.78%	-13.65%	-12.56%	-17.85%
Return on Capital (ROIC)	5.74%	-4.19%	-7.17%	-18.77%	-16.46%	-23.80%
Earnings Yield	0.07%	-0.92%	-1.83%	-3.87%	-4.21%	-5.68%
FCF Yield	0.37%	-0.14%	0.18%	-2.10%	-3.54%	-4.54%
Buyback Yield / Dilution	-4.82%	-2.20%	-2.64%	-2.73%	-3.01%	-5.24%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.